Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialBruce E. Sands, Olga Fedorishina, Emese Mihály et al.|The Lancet|2022Cited by 295
Efficacy of Therapy for Eosinophilic Esophagitis in Real-World PracticeEmilio J. Laserna‐Mendieta, Alfredo J. Lucendo, Sergio Casabona et al.|Clinical Gastroenterology and Hepatology|2020Cited by 107
Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT RegistryPilar Navarro, Alfredo J. Lucendo, Emilio J. Laserna‐Mendieta et al.|United European Gastroenterology Journal|2022Cited by 36
Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registryEmilio J. Laserna‐Mendieta, Alfredo J. Lucendo, Pilar Navarro et al.|Digestive and Liver Disease|2022Cited by 33
EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in EuropeAlfredo J. Lucendo, Sara Feo‐Ortega, Cecílio Santander et al.|Therapeutic Advances in Gastroenterology|2022Cited by 28